EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 33 / Numéro 12 (Décembre 2017) Med Sci (Paris), 33 12 (2017) 1079-1088 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 33, Numéro 12, Décembre 2017
Page(s) 1079 - 1088
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20173312015
Publié en ligne 20 décembre 2017
  1. Rigourd V, Chelbi ST, Vaiman D. La pré-éclampsie. Med Sci (Paris) 2008 ; 24 : 1017–1019. [CrossRef] [Google Scholar]
  2. Robillard PY, Scioscia M, Coppola D, et al. La « Donna di Ostuni », a case of eclampsia 28,000 years ago?. J Matern Fetal Neonatal Med 2017 : 1–4. [Google Scholar]
  3. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011 ; 123 : 2856–2869. [CrossRef] [PubMed] [Google Scholar]
  4. Sergent F, Hoffmann P, Brouillet S, et al. Sustained endocrine gland-derived vascular endothelial growth factor levels beyond the first trimester of pregnancy display phenotypic and functional changes associated with the pathogenesis of pregnancy-induced hypertension. Hypertension 2016 ; 68 : 148–156. [CrossRef] [PubMed] [Google Scholar]
  5. Vikse BE, Irgens LM, Leivestad T, et al. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008 ; 359 : 800–809. [Google Scholar]
  6. Timpka S, Macdonald-Wallis C, Hughes AD, et al. Hypertensive disorders of pregnancy and offspring cardiac structure and function in adolescence. J Am Heart Assoc 2016; 5. [Google Scholar]
  7. Buffat C, Mondon F, Rigourd V, et al. A hierarchical analysis of transcriptome alterations in intrauterine growth restriction (IUGR) reveals common pathophysiological pathways in mammals. J Pathol 2007 ; 213 : 337–346. [CrossRef] [PubMed] [Google Scholar]
  8. Amaral LM, Cunningham MW Jr., Cornelius DC, LaMarca B. Preeclampsia: long-term consequences for vascular health. Vasc Health Risk Manag 2015 ; 11 : 403–415. [Google Scholar]
  9. van Kesteren F, Visser S, Hermes W, et al. Prevention of cardiovascular risk in women who had hypertension during pregnancy after 36 weeks gestation. Hypertens Pregnancy 2015 ; 34 : 261–269. [CrossRef] [PubMed] [Google Scholar]
  10. Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension 2010 ; 56 : 166–171. [CrossRef] [PubMed] [Google Scholar]
  11. Cnattingius S, Reilly M, Pawitan Y, Lichtenstein P. Maternal and fetal genetic factors account for most of familial aggregation of preeclampsia: a population-based Swedish cohort study. Am J Med Genet A 2004; 130A : 365–371. [CrossRef] [PubMed] [Google Scholar]
  12. Staines-Urias E, Paez MC, Doyle P, et al. Genetic association studies in pre-eclampsia: systematic meta-analyses and field synopsis. Int J Epidemiol 2012 ; 41 : 1764–1775. [CrossRef] [PubMed] [Google Scholar]
  13. McGinnis R, Steinthorsdottir V, Williams NO, et al. Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. Nat Genet 2017 ; 49 : 1255–1260. [Google Scholar]
  14. Chelbi ST, Wilson ML, Veillard AC, et al. Genetic and epigenetic mechanisms collaborate to control SERPINA3 expression and its association with placental diseases. Hum Mol Genet 2012 ; 21 : 1968–1978. [CrossRef] [PubMed] [Google Scholar]
  15. Vaiman D. Genes, epigenetics and miRNA regulation in the placenta. Placenta 2017 ; 52 : 127–133. [CrossRef] [PubMed] [Google Scholar]
  16. Doridot L, Miralles F, Barbaux S, Vaiman D. Trophoblasts, invasion, and microRNA. Front Genet 2013 ; 4 : 248. [CrossRef] [PubMed] [Google Scholar]
  17. Lagana AS, Vitale SG, Sapia F, et al. miRNA expression for early diagnosis of preeclampsia onset: hope or hype?. J Matern Fetal Neonatal Med 2017 : 1–5. [Google Scholar]
  18. LaMarca B, Cornelius D, Wallace K. Elucidating immune mechanisms causing hypertension during pregnancy. Physiology (Bethesda) 2013 ; 28 : 225–233. [PubMed] [Google Scholar]
  19. Robillard PY, Hulsey TC. Association of pregnancy-induced-hypertension, pre-eclampsia, and eclampsia with duration of sexual cohabitation before conception. Lancet 1996 ; 347 : 619. [CrossRef] [PubMed] [Google Scholar]
  20. Hiby SE, Apps R, Sharkey AM, et al. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest 2010 ; 120 : 4102–4110. [CrossRef] [PubMed] [Google Scholar]
  21. Schwede S, Alfer J, von Rango U. Differences in regulatory T-cell and dendritic cell pattern in decidual tissue of placenta accreta/increta cases. Placenta 2014 ; 35 : 378–385. [CrossRef] [PubMed] [Google Scholar]
  22. Kalyanaraman B. Teaching the basics of redox biology to medical and graduate students: Oxidants, antioxidants and disease mechanisms. Redox Biol 2013 ; 1 : 244–257. [CrossRef] [PubMed] [Google Scholar]
  23. Elliot MG. Oxidative stress and the evolutionary origins of preeclampsia. J Reprod Immunol 2016 ; 114 : 75–80. [CrossRef] [PubMed] [Google Scholar]
  24. Challier JC, Uzan S. Le placenta humain et ses pathologies : l’oxygène en question. Med Sci (Paris) 2003 ; 19 : 1111–1120. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  25. Shi Z, Long W, Zhao C, et al. Comparative proteomics analysis suggests that placental mitochondria are involved in the development of pre-eclampsia. PLoS One 2013 ; 8 : e64351. [CrossRef] [PubMed] [Google Scholar]
  26. Many A, Hubel CA, Fisher SJ, et al. Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. Am J Pathol 2000 ; 156 : 321–331. [CrossRef] [PubMed] [Google Scholar]
  27. Matsubara K, Matsubara Y, Hyodo S, et al. Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. J Obstet Gynaecol Res 2010 ; 36 : 239–247. [CrossRef] [PubMed] [Google Scholar]
  28. Dechend R, Viedt C, Muller DN, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003 ; 107 : 1632–1639. [CrossRef] [PubMed] [Google Scholar]
  29. Myatt L. Review: Reactive oxygen and nitrogen species and functional adaptation of the placenta. Placenta 2010 ; 31 (suppl) : S66–S69. [CrossRef] [PubMed] [Google Scholar]
  30. Sanchez-Aranguren LC, Prada CE, Riano-Medina CE, Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol 2014 ; 5 : 372. [CrossRef] [PubMed] [Google Scholar]
  31. Bilodeau JF. Review: maternal and placental antioxidant response to preeclampsia – impact on vasoactive eicosanoids. Placenta 2014 ; 35 (suppl) : S32–S38. [CrossRef] [PubMed] [Google Scholar]
  32. Erlandsson L, Naav A, Hennessy A, et al. Inventory of Novel Animal Models Addressing Etiology of Preeclampsia in the Development of New Therapeutic/Intervention Opportunities. Am J Reprod Immunol 2016 ; 75 : 402–410. [Google Scholar]
  33. Orendi K, Gauster M, Moser G, et al. Effects of vitamins C and E, acetylsalicylic acid and heparin on fusion, beta-hCG and PP13 expression in BeWo cells. Placenta 2010 ; 31 : 431–438. [CrossRef] [PubMed] [Google Scholar]
  34. Rigourd V, Chauvet C, Chelbi ST, et al. STOX1 overexpression in choriocarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas. PLoS One 2008 ; 3 : e3905. [CrossRef] [PubMed] [Google Scholar]
  35. Goulopoulou S, Davidge ST. Molecular mechanisms of maternal vascular dysfunction in preeclampsia. Trends Mol Med 2015 ; 21 : 88–97. [CrossRef] [PubMed] [Google Scholar]
  36. Calicchio R, Buffat C, Mathieu JR, et al. Preeclamptic plasma induces transcription modifications involving the AP-1 transcriptional regulator JDP2 in endothelial cells. Am J Pathol 2013 ; 183 : 1993–2006. [CrossRef] [PubMed] [Google Scholar]
  37. Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ 2016 ; 353 : i1753. [Google Scholar]
  38. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017 ; 377 : 613–622. [Google Scholar]
  39. Poon LC, Wright D, Rolnik DL, et al. Aspirin for evidence-based preeclampsia prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. Am J Obstet Gynecol 2017; pii : S0002–9378(17)30929–8. doi: 10.1016/j.ajog.2017.07.038. [Google Scholar]
  40. Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med 2016 ; 374 : 13–22. [Google Scholar]
  41. Rodger MA, Gris JC, de Vries JIP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet 2016 ; 388 : 2629–2641. [CrossRef] [PubMed] [Google Scholar]
  42. Lefkou E, Mamopoulos A, Dagklis T, et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin invest 2016 ; 126 : 2933–2940. [CrossRef] [PubMed] [Google Scholar]
  43. Gram M, Anderson UD, Johansson ME, et al. The human endogenous protection system against cell-free hemoglobin and heme is overwhelmed in preeclampsia and provides potential biomarkers and clinical indicators. PLoS One 2015 ; 10 : e0138111. [CrossRef] [PubMed] [Google Scholar]
  44. Brownfoot FC, Hastie R, Hannan NJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol 2016 ; 214 : 356 e1–15. [Google Scholar]
  45. King A, Ndifon C, Lui S, et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci Adv 2016 ; 2 : e1600349. [CrossRef] [PubMed] [Google Scholar]
  46. Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011 ; 124 : 940–950. [CrossRef] [PubMed] [Google Scholar]
  47. Brouillet S, Hoffmann P, Alfaidy N, Feige JJ. Prokinéticines. De nouveaux peptides régulateurs de la reproduction humaine. Med Sci (Paris) 2014 ; 30 : 274–279. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.